Spero Therapeutics Shares Slump on $105M Funding Deal with KKR

Key Facts

In a move reflecting the ongoing challenges biotech firms face in securing liquidity, Spero Therapeutics shares declined following the announcement of a strategic funding agreement. The company entered into a $105 million financing deal with investment firm KKR. According to reports, the market reacted negatively to the news, as investors likely focused on the specific terms of the deal or the potential for shareholder dilution despite the significant capital injection.

This development comes as biotech companies increasingly turn to private equity for capital amidst volatile public markets. While the $105 million provides Spero with an extended cash runway, direct funding deals often trigger immediate selling pressure. Per market data, KKR shares closed at $96.91 on July 13, 2026, remaining relatively stable compared to the sharp reaction seen in Spero's valuation following the announcement.

Looking ahead, market participants will be watching the FOMC Minutes scheduled for July 8, 2026, for broader signals on interest rate paths that impact high-growth sectors. For Spero, the focus shifts to how this capital will be deployed in its clinical pipeline. KKR was trading at $96.91 (close July 13, 2026), maintaining a steady position within its daily range of $95.78 to $97.78.